- Home
- IMOS vs NBTX Comparison
IMOS vs NBTX Comparison
Compare IMOS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | NBTX |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | Taiwan | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IMOS | NBTX |
|---|---|---|
| Price | $40.51 | $32.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 40.4K | ★ 43.9K |
| Earning Date | 02-24-2026 | 03-17-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.97 | $11.73 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.78 | $2.99 |
| 52 Week High | $45.43 | $41.89 |
Technical Indicators
Market Signals| Indicator | IMOS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 55.20 |
| Support Level | $36.10 | $20.11 |
| Resistance Level | $45.24 | $41.89 |
| Average True Range (ATR) | 1.47 | 2.83 |
| MACD | 0.01 | -0.37 |
| Stochastic Oscillator | 47.64 | 32.64 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.